SecBot SecBot

APGE drug pipeline

Apogee Therapeutics, Inc. · 2 rated drugs
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Nov 2026
    zumilokibart
    Phase 2 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2 complete (positive); Phase 3 planned/initiating 2H 2026
Time to marketPhase 3 initiation guided to 2H 2026 with a company-flagged potential 2029 commercial launch in atopic dermatitis — roughly 3 years from now, assuming Phase 3 success and a standard filing/PDUFA path.

zumilokibart Updated Aug 3

What to watch

For APGE holders, the drug's upside is essentially monetized, the stock trades ~0.7% below the $135.11 all-cash offer, so the remaining question is simply whether the AbbVie deal closes in Q3 2026 (mean analyst target $130.53 vs. price ~$134 reflects the capped upside). For AbbVie investors, zumilokibart is a 2030s thesis: watch Phase 3 initiation in atopic dermatitis (guided 2H 2026), interim data from the head-to-head versus Dupixent (2H 2026), and the ~$0.14 FY2026 EPS dilution the deal carries, the Phase 3 readouts that could validate the ~$10.9B price tag are years away.

Bull case
  • Strong Phase 2 efficacy: APEX Part B met all primary and secondary endpoints with high statistical significance, mid-dose EASI-75 of 65.9% vs. 23.4% placebo (41.9% placebo-adjusted, p<0.001), supporting advancement to Phase 3 in 2H 2026.
  • Durable 52-week maintenance data: APEX Part A showed 75%/85% of patients maintained EASI-75 and 86%/78% maintained vIGA 0/1 on every-3-month and every-6-month dosing, respectively, supporting a long-acting differentiation story.
  • Validated by AbbVie's $10.9B all-cash acquisition at $135.11/share (announced June 22, 2026, expected close Q3 2026), AbbVie's largest buyout in more than five years; the stock's 52-week range of $34.34–$134.46 shows the deal re-rated the asset ~4x from its low (AbbVie press release via news.abbvie.com; CNBC; SEC 8-K).
Bear case
  • Upside is capped for APGE holders: the stock (~$134.10) sits ~0.7% below the $135.11 cash offer, and the analyst consensus flipped to 'hold' (14 hold vs. 7 buy/strong buy; mean price target $130.53, median $135, implied upside 0.7%) after a wave of post-deal downgrades on June 22–24, 2026.
  • If the Q3 2026 close fails (antitrust, shareholder, or financing hitch), APGE stock would revert to a standalone clinical-stage valuation, the 52-week low was $34.34, and the deal premium would evaporate.
  • Phase 3 is unproven and the market is crowded: atopic dermatitis/type-2 inflammation is anchored by the entrenched Dupixent franchise and other approved IL-13 pathway drugs, so zumilokibart must win on dosing convenience and head-to-head data that don't yet exist (BioPharma Dive frames it explicitly as a 'Dupixent competitor').
● neutral
Impact
PhasePreclinical (Phase 1 for respiratory indications in planning)
Time to marketUnknown — a Phase 1 trial is only planned for 2026; if the combination succeeds through trials, any approval would likely be 5+ years away.

APG273 zumilokibart/APG333 co-formulation (anti-IL-13 + anti-TSLP) Updated Aug 3

What to watch

If you hold APGE, treat it as merger arbitrage: the stock (~$134.16) trades just below the $135.11/share all-cash offer, with close expected Q3 2026 pending shareholder approval. If you invest in ABBV, APG273 is a long-dated pipeline option, watch for Phase 1 initiation in asthma/COPD (planned 2026) and the merger close, but do not buy ABBV for APG273 alone; AbbVie itself ascribes it "modest value" at this early stage.

Bull case
  • Dual-mechanism design: combining IL-13 blockade (zumilokibart) with TSLP blockade (APG333) targets both central and local drivers of obstructive airway disease, with the stated goal of breaking the efficacy ceiling of monotherapies in asthma and COPD (Apogee pipeline page).
  • Component data are encouraging: APG333 Phase 1 showed a long half-life and suppressed type-2 inflammatory markers for up to six months after dosing, supporting a quarterly or twice-yearly dosing profile that could be a convenience advantage over current biologics (AbbVie press release; Synapse).
  • Post-close, the asset sits inside AbbVie, a $465B-market-cap pharma with deep immunology commercial infrastructure, and the $10.9B deal was framed by AbbVie as deepening its immunology portfolio; preclinical combo data were also presented at ATS 2025 (Larvol).
Bear case
  • APG273 has no clinical efficacy data of its own: it is preclinical with a Phase 1 trial only in the planning stage, and Synapse lists its highest R&D status as Preclinical, a first-human failure would end the program before any revenue.
  • The buyer itself assigns 'modest value to APG273 given early stage of development' and expects the deal to cut adjusted diluted EPS by ~$0.14 in 2026 and ~$0.46 in 2027 (AbbVie investor deck / 8-K).
  • For APGE shareholders, upside is capped at the deal price, the stock's remaining move is arbitrage spread, not drug news; any APG273 upside now belongs to ABBV, where it is immaterial (ABBV market cap ~$465B vs. a $10.9B deal).

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
zumilokibartA Study Evaluating APG777 in Atopic DermatitisPhase 2Active not recruiting470Nov 2026